Guggenheim Starts Tourmaline Bio (TRML) at Buy, views "TOUR006 as a best-in-class anti-IL-6 therapy"
Tweet Send to a Friend
(Updated - October 31, 2023 6:12 AM EDT)
Guggenheim analyst Yatin Suneja initiates coverage on Tourmaline Bio (NASDAQ: TRML) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Guggenheim analyst Yatin Suneja initiates coverage on Tourmaline Bio (NASDAQ: TRML) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
